24/7 Market News Snapshot 18 November, 2024 – Fate Therapeutics, Inc. (NASDAQ:FATE)

November 18, 2024

DENVER, Colo., 18 November, 2024 (247marketnews.com) – (NASDAQ:FATE) are discussed in this article.
Fate Therapeutics, Inc. (NASDAQ:FATE), a leader in the development of iPSC-derived cellular immunotherapies, has experienced notable market activity, with its stock price surging 34.85% to $2.724 following a recent trading session. This increase is indicative of strong investor confidence, particularly in light of the company’s advancements in its clinical research programs. Current trading volumes have reached 3.41 million shares, pointing to heightened interest as the company continues to attract market attention.

In conjunction with this market momentum, Fate Therapeutics has made significant strides in its clinical trials, particularly with FT522, a novel off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate. FT522 is being evaluated in a Phase 1 clinical study for patients with relapsed/refractory B-cell lymphoma, as well as for its potential application in treating B-cell mediated autoimmune diseases. Recent presentations at the American College of Rheumatology Convergence have reinforced the encouraging safety profile of FT522, with patients exhibiting complete or partial responses.

The company intends to expand its investigation through a new Phase 1 study that will assess the combination of FT522 with existing induction and maintenance therapies in managing autoimmune diseases, including systemic lupus erythematosus and systemic sclerosis. “The data from our ongoing studies demonstrates FT522’s potential to offer therapeutic benefits without the drawbacks associated with traditional treatment regimens,” stated Scott Wolchko, President and CEO of Fate Therapeutics.

Fate Therapeutics is committed to leveraging its innovative iPSC platform to pioneer solutions that have the potential to transform patient care for those affected by cancer and autoimmune diseases, marking a significant phase in the evolution of immunotherapy.

Related news for (FATE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.